The oral drug by Merck & Co. smashes all competitors for the treatment and prevention of atherosclerosis.
A selective aldosterone synthase inhibitor for significantly lowering blood pressure.
Hua Medicine has figured out how to bring type 2 diabetes mellitus into long-term and sustained remission.
Ublituximab is the third anti-CD20 therapy for multiple sclerosis and a worthy rival to Ocrevus and Kesimpta.
Tisotumab vedotin for therapy of previously treated recurrent or metastatic cervical cancer.
Faricimab by Roche is a strong competitor to Eylea.
Atezolizumab with bevacizumab: a powerful immunotherapy approach for first-line therapy of liver cancer.